Table 1.
Characteristics of the included studies.
| Author/Year | Region | Study Type | Bacteria | Infection Type | No. of Patients (M) | No. of Patients (C) |
|---|---|---|---|---|---|---|
| Falagas, M.E., 2009 [23] | Greece | RETS | MDR AB (65.9%) | Mixed * | 23 | 118 |
| Batirel, A., 2014 [24] | Turkey | RETM | XRD AB | BSI | 36 | 102 |
| Yilmaz, G.R., 2015 [25] | Turkey | RETS | MDR AB XRD AB |
VAP | 17 | 33 |
| Paul, M., 2018 [26] | Israel | RCTM | CR AB | BSI, VAP, HAP, UTI | 151 | 161 |
| Park, S.Y., 2019 [27] | Korea | RETS | CR AB | BSI | 40 | 31 |
| Shi, H., 2019 [28] | Korea | RETS | CR AB | Pneumonia | 77 | 83 |
| Dickstein, Y., 2019 [29] | Israel | RCTM | CR AB | BSI, VAP, HAP, UTI | 135 | 131 |
| Nutman, A., 2020 [30] | Israel | RCTM | CR AB | BSI, VAP, HAP, UTI | 136 | 131 |
| Katip, W., 2020 [31] | Thailand | RETS | CR AB | BSI, pneumonia, UTI, surgical site infection | 124 | 124 |
| Seok, H., 2021 [32] | Korea | RETM | CR AB | BSI, UTI, Pneumonia | 58 | 41 |
| Author/Year |
CST
Loading Dose |
CST
Maintain Dose |
Meropenem Maintain Dose |
Duration of
Treatment |
||
| Falagas, M.E., 2009 [23] | No data | No data | No data | 17.9 days | ||
| Batirel, A., 2014 [24] | No loading dose | 5 mg/kg/day | 1.0 gm q8h | No data | ||
| Yilmaz, G.R., 2015 [25] | No data | 4.5 MU q12 h | 1.0 gm q8h | M:12.3 days C: 11.7 days |
||
| Paul, M., 2018 [26] | 9.0 MU | 4.5 MU q12 h | 2.0 gm q8h | No data | ||
| Park, S.Y., 2019 [27] | No data | 4.5 MU q12h | 1.0 gm q8h | M: 8.88 days C: 8.22 days |
||
| Shi, H., 2019 [28] | No data | 4.5 MU q12h | 2–3 gm/day | M: 12 days C: 14 days |
||
| Dickstein, Y., 2019 [29] | No data | No data | No data | No data | ||
| Nutman, A., 2020 [30] | 9.0 MU | 4.5 MU q12h | 2.0 gm q8h | No data | ||
| Katip, W., 2020 [31] | 9.0 MU | 4.5 MU q12h | 1.0 gm q8h | No data | ||
| Seok, H., 2021 [32] | No data | No data | No data | No data |
M: monotherapy; C: combination therapy; RETS: single center retrospective study; RETM: multicenter retrospective study; RCTM: multicenter randomized controlled trial; MDR: multidrug-resistance; XRD: extensive drug resistance; CR AB: carbapenem resistant Acinetobacter baumannii; BSI: blood stream infection; VAP: Ventilator-associated pneumonia; HAP: Hospital-acquired pneumonia; UTI: Urinary tract infection; CST: colistin; *: The infection site included pneumonia, urinary tract infection, skin/soft tissue infection, bacteremia, surgical infection, abdomen infection, orthopedic infection, catheter infection, and cerebrospinal fluid infection.